Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals. However, they may also cause large share price drops following bad news or missed expectations surrounding a company’s treatments. In my opinion, when investing in the biotech industry, it’s best to steer clear of smaller companies that are more susceptible to wild swings in their share price. It is much better to stick with larger companies that offer a wide array of treatments and increased growth potential. When choosing which biotech stocks to buy right now, I settled on companies that have experienced strong share price appreciation over this past year and a fair valuation, with a low forward P/E ratio compared to the sector overall. InvestorPlace - Stock Market News, Stock Advice & Trading Tips United Therapeutics (UTHR) In this photo illustration United Therapeutics Corporation (UTHR) logo is seen on a mobile phone screen. Source: viewimage / Shutterstock.com United Therapeutics (NASDAQ:UTHR) manufactures and commercializes treatments for life-threatening diseases primarily related to the lungs, such as pulmonary hypertension. Its products include Tyvaso, Remodulin, Adcirca, and Orenitram. Over the past year, its share price has increased by 40%, primarily due to its first-quarter earnings beat. On May 1, United Therapeutics reported earnings for the first quarter of 2024, stating that total revenue increased by 34% and net income rose by 27% compared to the previous year. Four of its flagship treatments reported double-digit sales growth year over year. UTHR is trading at a fair valuation, with a forward P/E ratio of 12.73, compared to the median sector forward P/E ratio of 19.61. UTHR offers investors upside potential due to its strong sales growth among many of its treatments. Halozyme Therapeutics (HALO) Physiotherapist doing healing treatment on patient leg. Therapist wearing blue uniform. Osteopathy, Chiropractic leg adjustment. Orthopedic therapy. ATIP stck. Source: Microgen / Shutterstock Halozyme Therapeutics (NASDAQ:HALO) operates a healthcare tech platform that provides subcutaneous drug delivery solutions along with other commercialized products related to proprietary enzymes. On May 7, Halozyme reported earnings for the first quarter of 2024, stating that total revenue increased by 21% and net income rose by 94%. It also announced a share buyback program with a limit of $750 million in repurchases. In June, HALO updated its full-year guidance for 2024, stating that expected total revenue is between $935 million and $1,015 million. This update in guidance comes after the patent approval regarding its product Enhanze. Halozyme is trading at a forward P/E ratio of 13.34, while the sector average is 19.61. HALO would be a great addition to an investment portfolio. It offers growth potential, especially following the recent patent approval and raised guidance. Amgen (AMGN) A magnifying glass zooms in on the website for Amgen Inc (AMGN). Source: Shutterstock Amgen (NASDAQ:AMGN) is a therapeutics manufacturer with products such as Enbrel, Otezla, Prolia, Xgeva, and Repatha, which treat a number of issues such as psoriasis, heart attack prevention, and osteoporosis. It also collaborates with other healthcare companies to develop and commercialize treatments. Over this past year, its share price has risen by 47%, partly due to its strong first-quarter earnings report. On May 2, Amgen reported its earnings for the first quarter of 2024. It stated that total revenue increased by 22%, several of its products reported year-over-year sales growth above double-digits, and its net income remained practically unchanged compared to the year before. Its stock price surged by roughly 12% following its first-quarter earnings report in which it confirmed positive data about its potential weight loss drug MariTide. Amgen has reported decent sales growth among several treatments, and total revenue for the full year 2024 is expected to be between $32. 5 billion and $33.8 billion. It is a solid choice for investors; it is a robust biotech stock that can offer investors increased returns, especially over the long term. Amgen is also trading at a decent valuation. Its forward P/E ratio is 16.97, while the sector average is 19.61. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. As of this writing, Noah Bolton did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Noah has about a year of freelance writing experience. He’s worked with Investopedia dealing with topics such as the stock market and financial news. More From InvestorPlace Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future” The post 3 Biotech Stocks to Buy Now: Q3 Edition appeared first on InvestorPlace.
3 Biotech Stocks to Buy Now: Q3 Edition
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...